These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Blocking the CD80 and CD86 costimulation molecules: lessons to be learned from animal models. Jonker M; Ossevoort And MA; Vierboom M Transplantation; 2002 Jan; 73(1 Suppl):S23-6. PubMed ID: 11810057 [TBL] [Abstract][Full Text] [Related]
27. CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment. Zheng XX; Markees TG; Hancock WW; Li Y; Greiner DL; Li XC; Mordes JP; Sayegh MH; Rossini AA; Strom TB J Immunol; 1999 Apr; 162(8):4983-90. PubMed ID: 10202046 [TBL] [Abstract][Full Text] [Related]
28. Humanized anti-CD154 antibody therapy for the treatment of allograft rejection in nonhuman primates. Xu H; Tadaki DK; Elster EA; Burkly LC; Berning JD; Cruzata F; Kampen RL; Montgomery SP; Patterson NB; Harlan DM; Kirk AD Transplantation; 2002 Oct; 74(7):940-3. PubMed ID: 12394834 [TBL] [Abstract][Full Text] [Related]
29. Treatment with humanized monoclonal antibodies against CD80 and CD86 combined with sirolimus prolongs renal allograft survival in cynomolgus monkeys. Bîrsan T; Hausen B; Higgins JP; Hubble RW; Klupp J; Stalder M; Celniker A; Friedrich S; O'Hara RM; Morris RE Transplantation; 2003 Jun; 75(12):2106-13. PubMed ID: 12829920 [TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of ABI793, a novel human anti-human CD154 monoclonal antibody, in cynomolgus monkey renal allotransplantation. Schuler W; Bigaud M; Brinkmann V; Di Padova F; Geisse S; Gram H; Hungerford V; Kleuser B; Kristofic C; Menninger K; Tees R; Wieczorek G; Wilt C; Wioland C; Zurini M Transplantation; 2004 Mar; 77(5):717-26. PubMed ID: 15021835 [TBL] [Abstract][Full Text] [Related]
31. Costimulation blockade followed by a 12-week period of cyclosporine A facilitates prolonged drug-free survival of rhesus monkey kidney allografts. Haanstra KG; Sick EA; Ringers J; Wubben JA; Kuhn EM; Boon L; Jonker M Transplantation; 2005 Jun; 79(11):1623-6. PubMed ID: 15940054 [TBL] [Abstract][Full Text] [Related]
32. Effects of dose and duration of anti-CD154 antibody therapy in preventing renal allograft rejection in a nonhuman primate model. Xu H; Elster E; Batty D; Berning J; Burkly L; Kampen R; Swanson S; Tadaki D; Harlan D; Kirk A Transplant Proc; 2001; 33(1-2):223-4. PubMed ID: 11266788 [No Abstract] [Full Text] [Related]
33. Blocking CD40 - CD154 and CD80/CD86 - CD28 interactions during primary allogeneic stimulation results in T cell anergy and high IL-10 production. Van Gool SW; Vermeiren J; Rafiq K; Lorr K; de Boer M; Ceuppens JL Eur J Immunol; 1999 Aug; 29(8):2367-75. PubMed ID: 10458748 [TBL] [Abstract][Full Text] [Related]
34. Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis. Shimizu K; Schönbeck U; Mach F; Libby P; Mitchell RN J Immunol; 2000 Sep; 165(6):3506-18. PubMed ID: 10975872 [TBL] [Abstract][Full Text] [Related]
35. Differential graft-versus-leukaemia effect by CD28 and CD40 co-stimulatory blockade after graft-versus-host disease prophylaxis. Ohata J; Sakurai J; Saito K; Tani K; Asano S; Azuma M Clin Exp Immunol; 2002 Jul; 129(1):61-8. PubMed ID: 12100023 [TBL] [Abstract][Full Text] [Related]
36. Blockade of CD40-mediated signaling is sufficient for inducing islet but not skin transplantation tolerance. Phillips NE; Markees TG; Mordes JP; Greiner DL; Rossini AA J Immunol; 2003 Mar; 170(6):3015-23. PubMed ID: 12626555 [TBL] [Abstract][Full Text] [Related]
37. Transient blocking of both B7.1 (CD80) and B7.2 (CD86) in addition to CD40-CD40L interaction fully abrogates the immune response following systemic injection of adenovirus vector. Ziller C; Stoeckel F; Boon L; Haegel-Kronenberger H Gene Ther; 2002 May; 9(9):537-46. PubMed ID: 11973629 [TBL] [Abstract][Full Text] [Related]
38. CTLA-4 on alloreactive CD4 T cells interacts with recipient CD80/86 to promote tolerance. Kurtz J; Raval F; Vallot C; Der J; Sykes M Blood; 2009 Apr; 113(15):3475-84. PubMed ID: 19179471 [TBL] [Abstract][Full Text] [Related]
39. Prolongation of primate cardiac allograft survival by treatment with ANTI-CD40 ligand (CD154) antibody. Pierson RN; Chang AC; Blum MG; Blair KS; Scott MA; Atkinson JB; Collins BJ; Zhang JP; Thomas DW; Burkly LC; Miller GG Transplantation; 1999 Dec; 68(11):1800-5. PubMed ID: 10609959 [TBL] [Abstract][Full Text] [Related]
40. Treatment of allograft recipients with donor-specific transfusion and anti-CD154 antibody leads to deletion of alloreactive CD8+ T cells and prolonged graft survival in a CTLA4-dependent manner. Iwakoshi NN; Mordes JP; Markees TG; Phillips NE; Rossini AA; Greiner DL J Immunol; 2000 Jan; 164(1):512-21. PubMed ID: 10605049 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]